Mitochondrial ATP production is the main energy source for intracellular metabolic pathways (Schapira [@CR115]). The human mitochondrial (mt) ATP synthase, or complex V (EC 3.6.3.14) is the 5th multi subunit oxidative phosphorylation (OXPHOS) complex. It synthesizes ATP from ADP in the mitochondrial matrix using the energy provided by the proton electrochemical gradient (Capaldi et al. [@CR28]; Nijtmans et al. [@CR92]; Zeviani and Di Donato [@CR151]). To date, numerous mutations in the mtDNA encoded subunits a and A6L have been found, next to mutations in a structural subunit (subunit epsilon, (Mayr et al. [@CR83])), an assembly factor (ATP12, (De Meirleir et al. [@CR42])) and an ancillary factor (TMEM70, (Cizkova et al. [@CR33])) which are nuclear-encoded. Most of these mutations give rise to severe mitochondrial disease phenotypes, ranging from NARP ([N]{.ul}europathy, [A]{.ul}taxia, and [R]{.ul}etinitis [P]{.ul}igmentosa) or MILS ([M]{.ul}aternally [I]{.ul}nherited [L]{.ul}eigh [S]{.ul}yndrome) for subunit a mutations to neonatal mitochondrial encephalo(cardio)myopathy and dysmorphic features in patients with an *ATP12* or *TMEM70* gene mutation (De Meirleir et al. [@CR42]; Cizkova et al. [@CR33]). In this article, we have aimed to review the 5th OXPHOS complex with respect to architecture, function, assembly, pathology, current therapeutic options and future perspectives. The structure and, intriguingly, the oligomerization of complex V determine its function, the former by the so-called "rotary catalysis" (Devenish et al. [@CR47]) and the latter by influencing mitochondrial and cristae morphology (Strauss et al. [@CR126]), as will be discussed below.

ATP synthase: architecture (Fig. [1](#Fig1){ref-type="fig"}) {#Sec1}
============================================================

ATP synthase consists of two well defined protein entities: the F~1~ sector, a soluble portion situated in the mitochondrial matrix, and the F~o~ sector, bound to the inner mitochondrial membrane. F~1~ is composed of three copies of each of subunits α and β, and one each of subunits γ, δ and ε. F~1~ subunits γ, δ and ε constitute the central stalk of complex V. F~o~ consists of a subunit c-ring (probably comprising eight copies, as shown in bovine mitochondria (Watt et al. [@CR146])) and one copy each of subunits a, b, d, F~6~ and the oligomycin sensitivity-conferring protein (OSCP). Subunits b, d, F~6~ and OSCP form the peripheral stalk which lies to one side of the complex. A number of additional subunits (e, f, g, and A6L), all spanning the membrane, are associated with F~o~ (Walker and Dickson [@CR142]; Devenish et al. [@CR47]). Two of the F~o~ subunits, subunit a and subunit A6L are encoded by the mtDNA *ATP6* and *ATP8* genes, respectively (Anderson et al. [@CR7]). The detailed structure of most of the bovine mitochondrial complex V subunits, which will not be covered in this review, has been resolved by X-ray crystallography by John Walker and his group (see, among others, (Stock et al. [@CR125]; Gibbons et al. [@CR52]; Cabezon et al. [@CR22]; Arechaga et al. [@CR8]; Cabezon et al. [@CR23]; Dickson et al. [@CR48]; Walker and Dickson [@CR142]; Rees et al. [@CR109])).Fig. 1Human mitochondrial ATP synthase, or complex V, consists of two functional domains, F~1~ and F~o~. F~1~ comprises 5 different subunits (three α, three β, and one γ, δ and ε) and is situated in the mitochondrial matrix. F~o~ contains subunits c, a, b, d, F~6~, OSCP and the accessory subunits e, f, g and A6L. F~1~ subunits γ, δ and ε constitute the central stalk of complex V. Subunits b, d, F~6~ and OSCP form the peripheral stalk. Protons pass from the intermembrane space to the matrix through F~o~, which transfers the energy created by the proton electrochemical gradient to F~1~, where ADP is phosphorylated to ATP. One β subunit is taken out to visualize the central stalk

For comparison, the subunit composition of human, yeast and *E. coli* ATP synthase is presented in Table [1](#Tab1){ref-type="table"} (Kucharczyk et al. [@CR70], [@CR71], [@CR72]; Watt et al. [@CR146]).Table 1Subunit composition of human, yeast and *E. coli* ATP synthase (Kucharczyk et al. [@CR70], [@CR71], [@CR72]; Watt et al. [@CR146])StoichiometryBacteriaMitochondria*E. coliS. cerevisiaeH. sapiens*F~1~3ααα3βββ1γγγ1εδδ1-εε1δOSCPOSCPF~o~1a6a1-8A6L10-15c~10-12~9~10~c~8~1-2b~2~4b1-dd1-hF~6~1-fft.b.d.-eet.b.d.-gg1-i-1-k-Regulators1-Inh1pIF~1~t.b.d.-Stf1p-t.b.d.-Stf2p-t.b.d.: to be determined

How structure relates to function: the rotary F~1~F~o~ ATP synthase {#Sec2}
===================================================================

The function of ATP synthase is to synthesize ATP from ADP and inorganic phosphate (P~i~) in the F~1~ sector. This is possible due to energy derived from a gradient of protons which cross the inner mitochondrial membrane from the intermembrane space into the matrix through the F~o~ portion of the enzyme. The proton gradient establishes a proton-motive force, which has two components: a pH differential and an electrical membrane potential (Δψ~m~) (Campanella et al. [@CR27]). The released energy causes rotation of two rotary motors: the ring of c subunits in F~o~ (Cox et al. [@CR36]) (relative to subunit a), along with subunits γ, δ and ε in F~1~ (Boyer and Kohlbrenner [@CR19]), to which it is attached. Protons pass F~o~ via subunit a to the c-ring (Wittig and Schagger [@CR148]). Rotation of subunit γ within the F~1~ α~3~β~3~ hexamer provides energy for ATP synthesis. This is called "rotary catalysis" (Devenish et al. [@CR47]) and can be explained by the "binding-change" mechanism, first proposed by Boyer (Boyer [@CR17]). This mechanism describes ATP synthesis and ATP hydrolysis at the catalytic sites, located in each of the three β subunits, at the interface with an adjacent α subunit. In the case of ATP synthesis, each site switches cooperatively through conformations in which ADP and P~i~ bind, ATP is formed, and then released. ATP hydrolysis uses the same pathway, but in reverse (Adachi et al. [@CR4]). These transitions are caused by rotation of the γ subunit. The α~3~β~3~ hexamer must remain fixed relative to subunit a during catalysis, this occurs through the peripheral stalk. Complex V can therefore mechanically be divided into "rotor" (c-ring, γ, δ, ε) and "stator" (α~3~β~3,~ a, b, d, F~6~, OSCP) components (Devenish et al. [@CR47]).

Oligomycin is an inhibitor of proton translocation in ATP synthase, putatively binding the F~o~ subunits a and c (Devenish et al. [@CR46]).

F~1~F~o~ ATP synthases, or F-type ATPases, belong to a bigger rotor protein family, consisting of F-, V-, and A-type ATPases (Cross and Muller [@CR38]; Lee et al. [@CR76]). The different ATPases are categorized on the basis of their function and taxonomic origin. They are related in both structure and mechanism (Toei et al. [@CR133]). F-type ATPases synthesize ATP, but are also capable of the reversed reaction and can hydrolyze ATP. Vacuolar or V-type ATPases use the energy derived from ATP hydrolysis to pump protons through membranes (Lee et al. [@CR76]). V-ATPases are localized to intracellular membranes where they acidify intracellular compartments (e.g., lysosomes). They also lie in the plasma membrane, to transport protons out of highly specialized cells, like kidney cells or osteoclasts (Toei et al. [@CR133]). Eukaryotes contain both F- and V-ATPases. In contrast, archaea typically contain only one complex which is evolutionarily closer to V-ATPases, called A-ATPase/synthase (Lee et al. [@CR76]). A-ATPases are structurally simpler than F- or V-ATPases, but functionally more versatile, performing both ATP synthesis and ATP hydrolysis (Lee et al. [@CR76]). F-type ATP synthases contain only one peripheral stalk, while A- and V-ATPases have two and three peripheral stalks, respectively, each made of an E-G heterodimer (Lee et al. [@CR76]).

Proteins related to mammalian ATP synthase {#Sec3}
==========================================

Coupling factors: the inhibitor protein IF~1~ and factor B {#Sec4}
----------------------------------------------------------

In normally respiring mitochondria, Δψ~m~ is high (estimated at between 150 and 180 mV negative to the cytosol), favoring ATP synthesis by F~1~F~o~ ATP synthase (Campanella et al. [@CR27]). However, when mitochondrial respiration is compromised and Δψ~m~ falls below a threshold, F~1~F~o~ ATP synthase can reverse, hydrolyzing ATP to pump protons through the membrane. Since depletion of ATP precipitates cell death, wasteful hydrolysis of ATP is not desirable, and must be prevented during inhibition of respiration (Devenish et al. [@CR47]). This regulation is carried out by the inhibitor protein IF~1~, which inhibits mitochondrial F~1~-ATPase activity (Pullman and Monroy [@CR102]) in a pH-dependent manner (Van Heeke et al. [@CR136]). The active form predominates at pH values \< 6.5 (Cabezon et al. [@CR21]). IF~1~ conserves ATP at the expense of Δψ~m,~ which has been shown to be protective to cells during ischemia (Campanella et al. [@CR26], [@CR27]). IF~1~ acts as a homodimer, binding to two F~1~-ATPase sectors via subunits β and γ. IF~1~ has no prokaryotic counterpart but is highly conserved through evolution in eukaryotic species, which indicates its functional importance (Campanella et al. [@CR27]). Remarkably, an increased IF~1~ expression - as found in certain tumors and cancer cells -- will inhibit both the synthetic and hydrolytic activities of complex V (Sanchez-Cenizo et al. [@CR111]).

Factor B, which has no prokaryotic homologue nor a counterpart in *Saccharomyces cerevisiae*, appears to bind to F~o~ on the matrix side (Belogrudov and Hatefi [@CR14]). It seems to have a regulatory function, like IF~1~. In addition to the classic proton-translocating pathway in F~o~, situated at the interface of subunit a and the c-ring, it has been proposed that the membrane sector F~o~ of animal mitochondria could harbor a second, latent proton-translocating pathway, to the assembly of which supernumerary subunits e, f, g, and A6L, as well as the ADP/ATP carrier could contribute their transmembrane segments (Belogrudov [@CR13]). It has further been proposed that factor B occludes the latent proton-translocating pathway (Belogrudov [@CR13]). Doing so, factor B blocks a proton leak, keeping Δψ~m~ high and thus favoring ATP synthase activity (Belogrudov [@CR13]).

Assembly factors: ATP11 and ATP12 {#Sec5}
---------------------------------

ATP11 and ATP12 bind to unassembled β and α subunits, respectively, by shielding their hydrophobic surfaces (Wang et al. [@CR144]; Ackerman [@CR2]). In the absence of these assembly factors, the α-F~1~ and β-F~1~ aggregate within large inclusion bodies in the mitochondrial matrix (Ackerman and Tzagoloff [@CR3]; Lefebvre-Legendre et al. [@CR77]).

TMEM70 {#Sec6}
------

Transmembrane protein 70 (TMEM70) has been shown to be localized in mitochondria (Calvo et al. [@CR24]). The N-terminal part of the cytosolic 29 kDa precursor is cleaved to a 21 kDa mature mitochondrial protein (Hejzlarova et al. [@CR54]). Analysis of submitochondrial fractions has shown that TMEM70 is associated with the inner mitochondrial membrane (Hejzlarova et al. [@CR54]). It has been demonstrated that TMEM70 is required to maintain normal expression levels and activity of complex V (Cizkova et al. [@CR33]). It however does not interact directly with holocomplex V (Hejzlarova et al. [@CR54]). A transient binding to complex V assembly intermediates has been proposed (Cameron et al. [@CR25]). Since TMEM70 is a low abundant mitochondrial protein, like the ATP11 and ATP12 assembly factors, a regulatory role of TMEM70 in complex V biogenesis has been suggested (Hejzlarova et al. [@CR54]). Further studies are necessary to clarify the exact mechanism by which TMEM70 defects lead to complex V deficiency.

Proteins associated with mammalian ATP synthase {#Sec7}
-----------------------------------------------

Two ATP synthase-associated membrane proteins were identified a few years ago (Meyer et al. [@CR85]). Both proteins had been identified earlier in a different context. The first one is a 6.8-kDa mitochondrial proteolipid (MLQ protein), the second one has been denoted as diabetes-associated protein in insulin-sensitive tissue (DAPIT) (AGP protein). It has been shown recently that DAPIT has a role in maintaining ATP synthase amount in mitochondria and therefore possibly can influence cellular energy metabolism (Ohsakaya et al. [@CR94]). The functional role of the 6.8-kDa proteolipid as ATP synthase-associated protein still has to be elucidated (Meyer et al. [@CR85]).

Complex V assembly {#Sec8}
==================

Current knowledge about the assembly of ATP synthase is mainly based on research performed on assembly-deficient yeast mutants (Kucharczyk et al. [@CR70], [@CR71], [@CR72]). Nevertheless complex V assembly remains puzzling and partially hypothetical because the biogenesis of ATP synthase is not easily studied biochemically (Rak et al. [@CR107]). This is due to rapid turnover of subunits of F~o~ and the stator in these yeast mutants (Rak et al. [@CR107]). This problem has been addressed lately by labeling and tracking the mitochondrial gene products of F~o~ in isolated mitochondria (Rak et al. [@CR108]).

It is known that the assembly of F~1~, the stator and the c-ring occurs separately, but the assembly sequence of subunits into the different modules and the sequence between the modules is not entirely clear (Velours and Arselin [@CR138]; Wittig et al. [@CR150]). Using clear native polyacrylamide gel electrophoresis (CN-PAGE), performed with milder detergents than blue native PAGE (BN-PAGE), it has been shown in human mitochondria lacking mtDNA (and therefore subunits a and A6L) that ATP synthase can assemble into a complex with a mass of 550 kDa (Wittig et al. [@CR150]). This is a little bit smaller than holocomplex V (597 kDa), suggesting that the only subunits lacking in the 550 kDa complex are subunit a (24.8 kDa) and A6L (8 kDa), and possibly the small associated proteins AGP and MLQ (Wittig et al. [@CR150]). This implies that the so-called F~1~-z complex (or V\* (Nijtmans et al. [@CR92])) contains the c-ring and that it is a breakdown product of the 550 kDa complex under the harsher conditions of BN-PAGE instead of an assembly intermediate (Wittig et al. [@CR150]). Based on these findings and on previous yeast work (reviewed in (Kucharczyk et al. [@CR70], [@CR71], [@CR72]; Rak et al. [@CR107])) a proposal regarding the assembly of mammalian ATP synthase has been made: assembly of the c-ring followed by binding of F~1~, the stator arm, and finally of subunits a and A6L (Wittig et al. [@CR150]) (Fig. [2](#Fig2){ref-type="fig"}). A recent yeast study indicated that ATP synthase is formed from three different modules: the c-ring, F~1~ and the Atp6p/Atp8p complex (Rak et al. [@CR108]). It is proposed that ATP synthase assembly in yeast involves two separate pathways (F~1~/Atp9p and Atp6p/Atp8p/2 stator subunits/Atp10p chaperone) that converge at the end stage (Rak et al. [@CR108]). The final addition of the mitochondrial encoded subunits to mammalian complex V is in line with the yeast studies describing that the expression of yeast subunits 6 and 8 is translationally regulated by the F~1~ sector (Rak and Tzagoloff [@CR104]; Rak et al. [@CR108]). Therefore a balanced output can be achieved between the nuclear encoded and mtDNA encoded subunits. The role of complex V subunits in the assembly process has been studied. The peripheral stalk is important for the stability of the c-ring/F~1~ complex (Rak et al. [@CR107]). It has been described that subunit A6L provides a physical link between the proton channel and the other subunits of the peripheral stalk (Stephens et al. [@CR124]). F~1~ subunit ε is indispensable for the assembly of holocomplex V (Havlickova et al. [@CR53]). More specifically, subunit ε plays a role in the biosynthesis and assembly of the F~1~ sector and seems to be involved in the incorporation of subunit c to the rotor structure of ATP synthase (Mayr et al. [@CR83]). Subunit c isoforms (P1, P2, and P3) are not functionally interchangeable since their targeting peptides have different roles, varying from mitochondrial import to the regulation of the assembly and function of other OXPHOS complexes (Vives-Bauza et al. [@CR140]). On the contrary, an example of over engineering is the F~1~ subunit γ, which only needs its N-terminal helix together with subunit δ in an upward position to catalyze ATP synthesis (Iino et al. [@CR59]; Mnatsakanyan et al. [@CR88]).Fig. 2Complex V assembly and dimerization. The current working model is based on assembly of the c-ring followed by binding of F~1~, the stator arm, and finally of subunits a and A6L. Two ATP synthase monomers dimerize via the F~o~ sector, where subunits a, e, g, b and A6L stabilize the monomer-monomer interface

Complex V di- and oligomerization {#Sec9}
=================================

An important role of subunits a and A6L is the stabilization of holocomplex V (Wittig et al. [@CR150]). It has been shown that ATP synthase is organized in dimers and higher oligomers (Arnold et al. [@CR9]; Schagger and Pfeiffer [@CR113]; Arselin et al. [@CR11]; Krause et al. [@CR69]; Wittig and Schagger [@CR147]; Thomas et al. [@CR131]; Wittig and Schagger [@CR148]). The interaction between two ATP synthase monomers mainly takes place via the F~o~ sector (Fig. [2](#Fig2){ref-type="fig"}). It has been suggested that subunit a forms the most important basis for dimerization since it has a high number of predicted transmembrane helices (Wittig and Schagger [@CR148]). Next to subunit a, subunits of the stator stalk and accessory subunits (e, g, b, and A6L) stabilize the monomer-monomer interface (Bisetto et al. [@CR15]; Wittig and Schagger [@CR148]; Wittig et al. [@CR150]). Another protein that has a role in the stabilization of di- and oligomers is IF~1~. Mature IF~1~ is only bound to di- and oligomeric ATP synthase in mammals (Wittig et al. [@CR150]). IF~1~ links two ATP synthases via the F~1~ sector (Devenish et al. [@CR47]).

Monocomplex V is fully capable of ATP synthesis. Nevertheless forming di- and oligomers has been proven to be beneficial to the cell. First, di- and oligomers provide stabilization of complex V, which is continuously subject to dynamic rotor/ stator interactions and can therefore be dissociated more easily (Wittig and Schagger [@CR149]). Secondly, oligomerization of complex V facilitates ATP synthesis (Strauss et al. [@CR126]). This happens because dimer ribbons of ATP synthase shape the inner mitochondrial membrane (Strauss et al. [@CR126]). Because of the angular association of two monomers, dimerization leads to bending of the inner mitochondrial membrane, creating protrusions of the membrane in the matrix, called mitochondrial cristae. Clustering of ATP synthase dimers at the apex of the cristae creates a strong local positive curvature which generates a proton trap. This facilitates ATP synthesis (Strauss et al. [@CR126]). IF~1~ contributes to this mechanism and is therefore beneficial during ischemia, since ATP synthesis can be preserved when mitochondrial respiration is compromised (Campanella et al. [@CR26], [@CR27]).

Complex V and mitochondrial morphology {#Sec10}
======================================

The association of ATP synthase dimers as generating the tubular cristae has been hypothesized by Allen (Allen [@CR6]). The link between dimerization of mitochondrial ATP synthase, through subunits *e*, *g*, and --as described just recently, subunits *i*, *k*, and the biogenesis of cristae has been provided by studying yeast cells (Paumard et al. [@CR97]; Thomas et al. [@CR131]; Wagner et al. [@CR141]). Due to cristae formation, the inner mitochondrial membrane can be divided into the inner boundary membrane and the cristae membrane. The cristae are connected to the inner boundary membrane by narrow structures, called crista junctions. In yeast, it has been suggested that the formation of cristae and crista junctions in mitochondria depends on antagonism between Fcj1 (formation of crista junction 1) and subunits *e*/*g* (Rabl et al. [@CR103]). IF~1~ contributes to cristae formation (Campanella et al. [@CR26]). Other components such as prohibitins or OPA1 or others yet to be identified also could contribute to crista junction and cristae tip formation (Rabl et al. [@CR103]; Zick et al. [@CR152]).

It has been shown in yeast that in the absence of complex V dimerization (by depleting subunits *e* and *g*) normal cristae formation is hampered, resulting in onion-like structures (Paumard et al. [@CR97]). Inhibition of F~1~ synthesis in yeast leads to an absence of cristae (Paumard et al. [@CR97]; Lefebvre-Legendre et al. [@CR77]). Another yeast study describes that the lack of Atp6p rather than an ATP production deficit modifies the overall structure of the mitochondria (Kucharczyk et al. [@CR70], [@CR71], [@CR72]). Taken together, the complex V structure and not its enzymatic activity seems to modify cristae morphology, which is in agreement with the necessity of ATP synthase dimerization for mitochondrial cristae formation (Paumard et al. [@CR97]; Campanella et al. [@CR26]; Strauss et al. [@CR126]).

Complex V deficiency {#Sec11}
====================

Complex V deficiency is one of the rarer OXPHOS deficiencies. Based on the results of mitochondrial biochemical diagnostics in Nijmegen in the years 2005-2009, complex I, IV and combined enzyme deficiencies are encountered most frequently (8%, 5% and 7%, respectively of 1,406 fresh muscle samples examined), followed by complex III (3%), complex II (2%) and complex V (1%) (Rodenburg [@CR110]).

Biochemical diagnosis {#Sec12}
---------------------

Measurement of the mitochondrial energy-generating system (MEGS) capacity in fresh muscle tissue is a powerful tool to assess mitochondrial function and to detect deficiencies of complex V and other OXPHOS complexes. The MEGS capacity can be examined in detail by measurement of ^14^CO2 production rates from oxidation of ^\[1-14C\]^pyruvate and carboxyl-14C-labeled TCA cycle intermediates in combination with measurement of ATP production in intact mitochondria from a muscle biopsy (Janssen et al. [@CR61]), or by examining mitochondrial respiration by measuring oxygen consumption in digitonin-permeabilized cells (Jonckheere et al. [@CR64]). A reduced pyruvate oxidation rate that is normalized by addition of an uncoupler, e.g. carbonyl cyanide 3-chlorophenyl hydrazone (CCCP), indicates a defect in complex V, the adenine nucleotide transporter, or the phosphate carrier (Rodenburg [@CR110]). Enzyme analysis of complex V (mtATPase) in skeletal muscle biopsy and in cultured fibroblasts remains the mainstay of the diagnostic process (Janssen et al. [@CR60]). In Nijmegen, mtATPase activity is measured spectrophotometrically in isolated mitochondria from fresh muscle tissue and fibroblasts as described (Rodenburg [@CR110]): a solution of 980 μl containing 250 mM sucrose, 50 mM KCl, 30 mM phosphate buffer pH 7.4, 25 mM phosphate buffer pH 8.0, 0.1 mM phosphoenolpyruvate, 5 mg/L Ap5A, 0.3% BSA, 0.2 mM EGTA, 3 mM ATP, 7.5 mM MgCl2, 250 μM NADH, 2.5 U/ml lactate dehydrogenase, and 1.5 U/ml pyruvate kinase is incubated for 10 min at 37°C. A mitochondrial suspension is freeze-thawed three times and 20 μl is added to the reaction mixture, mixed and transferred to a cuvette, after which the absorption at 340 nm is measured for 8 min. Simultaneously, the absorption is measured in a second cuvette after addition of 1 μl of an 8 mg/ml oligomycin solution in ethanol to the mitochondrial suspension and the reaction mixture. The oligomycin-sensitive activity of complex V is calculated using an ε~340~ for NADH of 6.22 × 10^3^ L/mol.cm and is expressed in units (the amount of enzyme required to convert 1 μmol NADH per min) per unit cytochrome oxidase (COX) (Cooperstein and Lazarow [@CR34]) activity. Analysis of complex V in frozen tissue is considered to be less reliable than in fresh muscle tissue ((Kirby et al. [@CR66]), and personal experience (data not shown)). In addition, BN-PAGE followed by western blotting (Schagger and von Jagow [@CR114]; Nijtmans et al. [@CR93]) and in-gel activity measurements of ATP hydrolysis (Nijtmans et al. [@CR93]) can be performed to assess the amount and activity of complex V. BN-PAGE can also provide information about the assembly of complex V (Cizkova et al. [@CR33]; Jonckheere et al. [@CR63]).

Molecular genetics {#Sec13}
------------------

Hitherto, complex V mutations have been described in the mtDNA encoded *ATP6* (*MT-ATP6*) and *ATP8* (*MT-ATP8*) genes. ATP synthase deficiency due to the nuclear encoded *ATP12* and *TMEM70* genes has also been described (De Meirleir et al. [@CR42]; Cizkova et al. [@CR33]). Interestingly, only one mutation has hitherto been described in a nuclear encoded structural complex V subunit, *ATP5E* (Mayr et al. [@CR83]).

ATP synthase subunit a; *MT-ATP6* (MIM ID +516060) {#Sec14}
--------------------------------------------------

Mutations in *MT-ATP6* were the first complex V genetic defects to be reported (Holt et al. [@CR55]) and have been described most frequently to date. The classical clinical picture is found in m.8993T\>G/C and m.9176T\>G/C mutations and covers a spectrum which varies between isolated ataxia, NARP, bilateral striatal necrosis, to Leigh or Leigh-like syndromes ([www.mitomap.org](http://www.mitomap.org)). Also other clinical features have been associated with *MT-ATP6* mutations ([www.mitomap.org](http://www.mitomap.org)). Below, an overview of a part of the hitherto described mutations in this gene is given, i.e., the mutations that have been well studied in humans and in yeast and those that, in our opinion, add interesting information regarding the clinical expression of mitochondrial complex V diseases. They have been outlined in relation to their clinical picture.

**m.8993T\>G** This mutation leads to NARP (typically \<90-95% heteroplasmy) or MILS (when \>95% heteroplasmy). Biochemically a decreased ATPase activity (measured spectrophotometrically) and a severely decreased ATP production rate (until 70% when \>90% heteroplasmy) is observed (Tatuch and Robinson [@CR129]; Trounce et al. [@CR134]; Baracca et al. [@CR12]; Garcia et al. [@CR51]; Pallotti et al. [@CR96]; Morava et al. [@CR89]; Sgarbi et al. [@CR118]). Subunit a has two functions: (i) it conducts protons from the inner mitochondrial membrane to the matrix, which (ii) leads to the rotation of the ring of c-subunits that contacts subunit a in the membrane. The resulting mechanical energy is used to induce conformational changes at the level of the catalytic sites in the F~1~ extra-membrane domain that favor ATP synthesis (Sgarbi et al. [@CR118]; Kucharczyk et al. [@CR73]). The m.8993T\>G point mutation leads to p.Leu156Arg. Leu156 is highly conserved in eukaryotes (Boyer [@CR18]; Sgarbi et al. [@CR118]) and is situated in the region of subunit a that regulates proton translocation coupled to rotation of the c-ring (Sgarbi et al. [@CR118]; Kucharczyk et al. [@CR70], [@CR71], [@CR72]). The introduction of a positively charged amino acid (arginine) instead of the hydrophobic leucine causes a structural change that has been shown to affect rotation of the c-ring (Sgarbi et al. [@CR118]). The proton flux through F~o~ is slower, but not blocked (Sgarbi et al. [@CR118]). Furthermore, it has been shown that ATP synthase still assembles and oligomerizes correctly. This is confirmed by an intact oligomycin sensitivity (Cortes-Hernandez et al. [@CR35]), a property that is lost when enzyme structure is severely altered (Matsuno-Yagi et al. [@CR81]; Penefsky [@CR98]). The assembly of F~1~ with F~o~ has only been shown to be delayed because of a slower subunit a synthesis or an increased subunit a instability and degradation (D\'Aurelio et al. [@CR40]). Taken together, the severe impairment of ATP synthesis is due to functional inhibition in a correctly assembled ATP synthase (Cortes-Hernandez et al. [@CR35]).

**m.8993T\>C** The clinical picture is similar to the m.8993T\>G mutation, but is generally milder (de Vries et al. [@CR43]; Vazquez-Memije et al. [@CR137]; Morava et al. [@CR89]; Debray et al. [@CR45]). The mutation results in p.Leu156Pro. Opposite to the positive charged arginine in the m.8993T\>G mutation, proline is a non-charged amino acid. Biochemically, ATP synthesis is not severely affected (Sgarbi et al. [@CR118]). So this does not fully explain the NARP or MILS phenotypes seen in patients. It has been shown that the m.8993T\>C mutation favors reactive oxygen species (ROS) production, which is believed to be the major pathogenic mechanism (Sgarbi et al. [@CR118]). ROS plays a major role in the pathogenesis of neurological diseases related to mitochondrial dysfunction (Lenaz et al. [@CR78]; Wallace [@CR143]).

**m.9176T\>G/C** The clinical picture is characterized by [f]{.ul}amilial [b]{.ul}ilateral [s]{.ul}triatal [n]{.ul}ecrosis (FBSN) and Leigh syndrome (Thyagarajan et al. [@CR132]; Dionisi-Vici et al. [@CR50]). A hereditary spastic paraplegia-like disorder has been described in a family carrying the homoplasmic m.9176T\>C mutation (Verny et al. [@CR139]). The mutations also change a highly conserved hydrophobic leucine residue into arginine (m.9176T\>G) or proline (m.9176T\>C) at position 217 of the protein. Position 217 of subunit a also lies in proximity to the c-ring (Kucharczyk et al. [@CR70], [@CR71], [@CR72]). It has been shown in human cells with a high degree of heteroplasmy that the m.9176T\>G mutation severely decreases the rate of ATP production (Carrozzo et al. [@CR30]). In yeast carrying the m.9176T\>G mutation, it has been described that that incorporation of subunit a into ATP synthase was almost completely prevented (Kucharczyk et al. [@CR70], [@CR71], [@CR72]). This resulted in a disturbed assembly which profoundly altered mitochondrial morphology (Kucharczyk et al. [@CR70], [@CR71], [@CR72]). This finding is in contrast to the m.8993T\>G mutation, where the assembly is not altered (as mentioned before). Taken together, the pathogenicity of m.9176T\>G may not be limited to a bio-energetic deficiency, but may also be attributed to an altered mitochondrial and cristae morphology (Kucharczyk et al. [@CR70], [@CR71], [@CR72]). Also the m.9176T\>C mutation has been studied in yeast, only showing a mild decrease in ATP production (Kucharczyk et al. [@CR73]). There is a poor correlation between genotype and phenotype for the m.9176T\>C mutation (Kucharczyk et al. [@CR73]). Additional determinants may be responsible and are a plausible explanation for this finding. One of these determinants has been proposed to be the higher degree of oligomycin vulnerability in the mutant than in wild type (Kucharczyk et al. [@CR73]).In tightly coupled mitochondria the oxygen consumption rate and ATP synthesis depend on each other (Rak et al. [@CR105], [@CR106]). Therefore it is not very surprising to see a decreased respiratory activity in many ATP synthase defective mutants (Rak et al. [@CR105], [@CR106]). In several yeast models with NARP-MILS mutations (atp6-p.Leu183Pro (Kucharczyk et al. [@CR70], [@CR71], [@CR72]), atp6-p.Leu183Arg (Rak et al. [@CR105], [@CR106]), atp6-p.Leu247Arg (Kucharczyk et al. [@CR70], [@CR71], [@CR72]), atp6-p.Leu247Pro (Kucharczyk et al. [@CR73]), and Δatp6 (Rak et al. [@CR105], [@CR106])), it has been shown that there is a linear correlation between ATP synthase activity and complex IV activity (Kucharczyk et al. [@CR73]). So it appears that complex IV is an important target for the co-regulation of electron transfer and ATP synthesis in mitochondria (Kucharczyk et al. [@CR73]).

**m.9035T\>C, m.9185T\>C, m.9191T\>C, m.8851T\>C** These mutations are illustrations of variants of the earlier described NARP-MILS clinical spectrum. m.9035T\>C has been found in a family with maternally transmitted cognitive developmental delay, learning disability, and progressive ataxia (Sikorska et al. [@CR121]). Mutant cybrids had less than half of the steady-state content of ATP and a substantial higher basal level of reactive oxygen species (ROS) (Sikorska et al. [@CR121]). m.9185T\>C (p.Leu220Pro) results in a phenotype varying from mild learning difficulties and foot deformities, ataxia, an acute neurological presentation with complete recovery, to Leigh syndrome (Moslemi et al. [@CR90]; Childs et al. [@CR31]). m.9191T\>C (p.Leu222Pro) has been described in a patient with Leigh syndrome (Moslemi et al. [@CR90]). The pathogenic mechanism of the m.9185T\>C and m.9191T\>C mutations is unknown, but they are situated in a highly conserved region of the protein. The observed phenotypical differences are proposed to result from additional genetic and/or environmental modifying factors (Childs et al. [@CR31]). A patient suffering from bilateral striatal necrosis and harboring a m.8851T\>C mutation has also been described (De Meirleir et al. [@CR41]). This phenotype is less severe than found in typical Leigh disease (De Meirleir et al. [@CR41]).

**ΔTA9205** This mutation has been reported in a patient with seizures and lactic acidemia (Seneca et al. [@CR117]). ΔTA9205 is situated at the junction between the two genes *MT-ATP6* and *MTCO3* (which codes for COX3, a complex IV subunit). It removes the termination codon from *RNA14*, the bi-cistronic RNA unit encoding *MT-ATP8* and *MT-ATP6*, which has been shown to cause a decrease in the steady-state level of the mutated *RNA14* (Temperley et al. [@CR130]). The level of *RNA15*, the RNA transcribed from *MTCO3*, is not affected (Temperley et al. [@CR130]). This mutation illustrates how a mtDNA mutation can influence the turnover of a human mitochondrial mRNA.

**Modifiers** Phenotypical variations between patients harboring the same mtDNA mutation have classically been attributed to mtDNA heteroplasmy. However, a discrepancy between the levels of mutant mtDNA and disease severity is sometimes observed (D\'Aurelio et al. [@CR40]). The mtDNA background has been shown to play an important role in modulating the biochemical defects and clinical outcome (D\'Aurelio et al. [@CR40]). *MT-ATP6* mutations m.8741T\>G and m.8795A \> G have been shown to be protective factors for the m.8993T\>G MILS mutation (Mkaouar-Rebai et al. [@CR86]). A *MT-ATP6* polymorphism, m.9055G\>A, significantly reduces the risk of Parkinson disease, especially in women (van der Walt et al. [@CR135]). The mitochondrial haplogroup J has been shown to be associated with longevity and protection against certain diseases (Verny et al. [@CR139]). Vice versa, respiratory chain defects upstream of ATP synthase contribute to ATP synthesis impairment, worsening the biochemical and clinical phenotype, e.g., of m.8993T\>G/C and m.9176T\>G mutations (D\'Aurelio et al. [@CR40]). The germ-line mutation m.8932C\>T has, together with somatic mtDNA mutations in the cytochrome oxidase subunit I (*COI*) gene, been associated with prostate cancer (Petros et al. [@CR99]; Arnold et al. [@CR10]). The mtDNA variants m.8836T\>G, m.9016A\>G, m.9101T\>C, m.9139G\>A have been linked with patients who had Leber hereditary optic neuropathy (LHON) or LHON-like optic neuropathies (Lamminen et al. [@CR75]; Povalko et al. [@CR101]; Abu-Amero and Bosley [@CR1]; La Morgia et al. [@CR74]). Hence, mtDNA background can explain the biochemical and clinical variations observed between patients with the same mutation and a comparable mutation load. This also illustrates the role of mtDNA variants in the complexity of mtDNA disease expression. In general, phenotypic variability is proposed to be the result of interactions between the casual genes, genetic background or modifier genes (mitochondrial or nuclear), and probably environmental factors (Carelli et al. [@CR29]).

ATP synthase subunit A6L; *MT-ATP8* (MIM ID +516070) {#Sec15}
----------------------------------------------------

**m.8529G\>A** This homoplasmic mutation has been found in a 16-year-old patient presenting with apical hypertrophic cardiomyopathy and neuropathy (Jonckheere et al. [@CR63]). The mutation is situated in an overlap region between *MT-ATP8* and *MT-ATP6*, resulting in a silent change in *MT-ATP6* (Met1Met; ATG\>ATA), but introducing a premature stopcodon in a conserved region of *MT-ATP8* (p.Trp55X) (Jonckheere et al. [@CR63]). This resulted in an improper assembly and a decreased activity of the complex V holoenzyme (Jonckheere et al. [@CR63]).

**m.8528T\>C** This homoplasmic mutation has been found in four unrelated patients who presented as infants with isolated hypertrophic cardiomyopathy and congestive heart failure, evolving to multisystem disease (Ware et al. [@CR145]). Electron microscopy of muscle tissue showed increased variation in size and shape of mitochondria with dense parallel cristae in one patient (Ware et al. [@CR145]). For A6L, m.8528T\>C (p. Trp55Arg) is a pathogenic missense mutation, replacing a hydrophobic tryptophan into a basic arginine in a conserved region of the subunit. In subunit a, the nucleotide alteration results in the change of the initiation methionine to threonine, but the effect of this mutation on the function of this subunit is not clear (Ware et al. [@CR145]).Taken together, the *MT-ATP8* mutations m.8529G\>A and m.8528T\>C both affect the same amino acid (tryptophan) and clinically cause a cardiomyopathy.

**m.8411A\>G** The de novo mutation with 97% heteroplasmy has been described in a patient with psychomotor delay, epilepsy, tetraplegia, congenital deafness, central blindness and swallowing difficulties (Mkaouar-Rebai et al. [@CR87]). He died at the age of 10 years. Brain MRI showed involvement of the interpeduncular nucleus, the central tegmental tract, the white matter and the cerebellum. This leucodystrophy phenotype differs from the other mutations described in *MT-ATP8*, where cardiac involvement predominates. Leucodystrophy has been described in two siblings with Leigh syndrome harboring the m.9176T\>C mutation in *MT-ATP6* (Hung and Wang [@CR58]). It should be noted that complex V enzyme analysis was not performed in this patient (Mkaouar-Rebai et al. [@CR87]), and therefore the pathogenicity of the m.8411A\>G mutation has not been firmly established yet.

*ATP12* (MIM ID \*608918) {#Sec16}
-------------------------

A homozygous T\>A mutation, changing an evolutionary conserved tryptophan to an arginine at position 94 (p.Trp94Arg) of the nuclear encoded complex V assembly gene *ATP12* has been found in a patient who presented with a severe neonatal encephalopathy and dysmorphic features, evolving to basal ganglia atrophy within months and death at the age of 14 months (De Meirleir et al. [@CR42]; Meulemans et al. [@CR84]). The mutation resulted in a severely decreased complex V amount and activity. It was hypothesized that the change of a neutral polar amino acid (tryptophan) into a basic one (arginine) resulted in an ATP12 protein that was no longer able to mediate F~1~ assembly (De Meirleir et al. [@CR42]). Later, it has been shown in a yeast model that the p.Trp94Arg mutation decreases the solubility of the protein, implying that the primary impact of the mutation was a change in physical rather than functional parameters (Meulemans et al. [@CR84]). Mitochondrial morphology has been studied in fibroblasts, but no alterations compared to control cells could be observed (Meulemans et al. [@CR84]).

*TMEM70* (MIM ID \*612418) {#Sec17}
--------------------------

The *TMEM70* gene encodes a mitochondrial protein, transmembrane protein 70. A common splice site mutation and an isolated frameshift mutation have been described in the *TMEM70* gene particularly in a homogeneous ethnic group (Romanies), with a clinical phenotype characterized by neonatal mitochondrial encephalocardiomyopathy, lactic acidosis and dysmorphic features (Cizkova et al. [@CR33]). The description of four novel mutations in the *TMEM70* gene has confirmed and expanded this classical clinical picture with early onset cataract, gastrointestinal dysfunction, congenital hypertonia and a fetal presentation of the syndrome (Spiegel et al. [@CR122]). One patient with a milder clinical phenotype carrying the common splice site mutation and a missense variant has also been described (Shchelochkov et al. [@CR120]). This phenotype corroborates with two reported patients who are compound heterozygous for the common splice site mutation and a frame-shift mutation in exon 1 (Honzik et al. [@CR56]; Cameron et al. [@CR25]). It was shown that *TMEM70* is required to maintain normal expression levels of complex V (Cizkova et al. [@CR33]). The exact mechanism behind this remains to be elucidated, although it has been suggested that TMEM70 is involved in complex V biogenesis (Cizkova et al. [@CR33]).

ATP synthase subunit epsilon; *ATP5E* (MIM ID \*606153) {#Sec18}
-------------------------------------------------------

Recently, a homozygous missense mutation c.35A\>G (p.Tyr12Cys) has been described in exon 2 of the *ATP5E* gene (Mayr et al. [@CR83]). The patient was a 22 year old woman presenting with neonatal onset, lactic acidosis, 3-methylglutaconic aciduria, and mild mental retardation. She developed peripheral neuropathy (Mayr et al. [@CR83]). The mutation caused a decrease in the amount and activity of holocomplex V. Remarkably, subunit c was found to accumulate, in contrast to the other investigated complex V subunits, and in contrast to what was found in patients with a mutation in the *TMEM70* (Honzik et al. [@CR56]) and *ATP12* (De Meirleir et al. [@CR42]) genes (Mayr et al. [@CR83]). Using pulse-chase experiments, this study pointed to the crucial role of subunit ε in the biosynthesis and assembly of the F~1~ part of ATP synthase. Moreover, subunit ε seems to be involved in the incorporation of subunit c into the rotor (Mayr et al. [@CR83]).

Therapy {#Sec19}
=======

Current available treatment options for patients with mitochondrial diseases are mainly supportive. Therefore, a lot of effort is put into the search for both pharmacological and genetic approaches to cure this devastating group of disorders (for reviews, see (DiMauro et al. [@CR49]; Koene and Smeitink [@CR67], [@CR68])). Focusing here on complex V deficiency, current research has mainly covered the therapy of mtDNA mutations.

Antioxidants {#Sec20}
------------

As mentioned above, complex V mutations can increase ROS production which is deleterious for the cell. The antioxidants N-acetylcysteine (NAC) and dihydrolipoic acid (DHLPA) have therefore been tested in fibroblasts harboring 97% m.8993T\>G mutant mtDNA. It has been shown that they significantly improved mitochondrial respiration and ATP synthesis in these cells (Mattiazzi et al. [@CR82]).

Substrates: α-Ketoglutarate/Aspartate {#Sec21}
-------------------------------------

In yeast studies, it has been suggested that forcing substrate-level phosphorylation to work overtime may counteract the energy crisis due to OXPHOS impairment (Schwimmer et al. [@CR116]).

For the application of this approach in OXPHOS-deficient human cells, exogenous substrates capable of stimulating the Krebs cycle flux while at the same time removing the excess of reduced nicotinamide adenine dinucleotide (NADH) have been chosen (Sgarbi et al. [@CR119]). It has been demonstrated that homoplasmic cybrids harboring the m.8893T\>G mutation were protected from cell death and had an ATP content similar to controls after supplementation of the culture medium with α-ketoglutarate and aspartate (Sgarbi et al. [@CR119]).

Affecting heteroplasmy of the mtDNA (gene-shifting) {#Sec22}
---------------------------------------------------

This genetic approach aims to force a shift in heteroplasmy, reducing the ratio of mutant to wild-type genomes (also called gene-shifting) (DiMauro et al. [@CR49]). Various methods can be applied to achieve this goal.

**Allotopic expression** Here, a normal version of a mutant mtDNA-encoded protein is imported into the nucleus. For example, *MT-ATP6* can be converted from the mitochondrial into the nuclear genetic code (Manfredi et al. [@CR80]; DiMauro et al. [@CR49]). To be transported to the mitochondrion, it has to be provided with a mitochondrial targeting signal, of which the genetic sequence can be borrowed from another mtDNA-encoded protein. The biochemical defect in cybrid cell lines harboring the m.8993T\>G mutation has been corrected successfully using this strategy (Manfredi et al. [@CR80]).

**Xenotopic expression** The correction here implies the transfection of mammalian cells with either mitochondrial or nuclear genes from other organisms encoding the protein of interest (DiMauro et al. [@CR49]). This has also been applied to human cybrids harboring the m.8993T\>G mutation by expressing the nDNA encoded ATPase6 protein of the alga *Clamydomonas reinhardtii*, which already possessed the mitochondrial targeting sequence since it is nuclear encoded (Ojaimi et al. [@CR95]). Also this approach could correct the biochemical defect in these cells (Ojaimi et al. [@CR95]).

**Restriction endonucleases** These are specific proteins that cut mutant mtDNA but not wild type mtDNA (DiMauro et al. [@CR49]). For example, the m.8993T\>G mutation creates a unique cleavage site for the restriction endonuclease *Sma*I. The gene for *Sma*I was fused to a mitochondrial targeting sequence and expressed in heteroplasmic mutant cybrid cells, which lost mutant mtDNA and recovered biochemically (Tanaka et al. [@CR128]; Alexeyev et al. [@CR5]).

**Oligomycin** It has been shown that culturing heteroplasmic m.8993T\>G cybrid cells in medium containing oligomycin (complex V inhibitor) and galactose (which forces the cells to rely on oxidative metabolism for ATP production) allowed for the selection of wild type over mutant mtDNA (Manfredi et al. [@CR79]).

Germline therapy {#Sec23}
----------------

It has been proposed that nuclear transfer techniques may be an approach for the prevention of transmission of human mtDNA disease (Sato et al. [@CR112]; Brown et al. [@CR20]). Briefly, this means that the pronucleus of an oocyte, or zygote, of a woman carrying mutated mtDNA could be transferred to a donor enucleated oocyte, or zygote, carrying wild type mtDNA (DiMauro et al. [@CR49]; Craven et al. [@CR37]). In that way, the offspring will carry all the nuclear -- and physiognomonic - traits of the parents, but not the mutated mtDNA of the mother (DiMauro et al. [@CR49]). Two successful approaches have recently been described.

**Metaphase II spindle transfer between unfertilized metaphase II oocytes** It has been demonstrated in mature non-human primate oocytes (*Macaca mulatta*) that the mitochondrial genome can be efficiently replaced by spindle-chromosomal complex transfer from one egg to an enucleated, mitochondrial-replete egg (Tachibana et al. [@CR127]). Subsequently, it was possible to have normal fertilization and embryo development. The offspring was healthy (Tachibana et al. [@CR127]).

**Pronuclear transfer between zygotes** This is essentially the same procedure, except that the nuclear material, both the male and female pronucleus, is removed after fertilization (Tachibana et al. [@CR127]). It has been shown that transfer of pronuclei between abnormally fertilized human zygotes resulted in minimal carry-over of donor zygote mtDNA and is compatible with onward development of the blastocyst stage in vitro (Craven et al. [@CR37]).There have been few randomized controlled trials for the treatment of mitochondrial disease (Chinnery et al. [@CR32]). To date, there is no clear evidence supporting the use of pharmacological agents, non-pharmacological treatments (vitamins and food supplements), and physical training in patients with mitochondrial disorders (Chinnery et al. [@CR32]). Although very promising, all genetic techniques are still in an experimental phase and different technical, ethical and safety issues still have to be solved (DiMauro et al. [@CR49]; Kucharczyk et al. [@CR70], [@CR71], [@CR72]; Tachibana et al. [@CR127]; Craven et al. [@CR37]). Nevertheless, they do allow cautious optimism for the future.

Prenatal and preimplantation diagnosis {#Sec24}
--------------------------------------

Since current therapeutic options for mitochondrial diseases are insufficient, the possibility of prenatal diagnosis for fetuses at risk is a valuable alternative. If it concerns a known nuclear genetic defect, the mutation can directly be searched for in fetal tissue. If the complex V deficiency is caused by a mtDNA defect (in *MT-ATP6* or *MT-ATP8*), prenatal diagnosis is complicated by several factors. First, the correlation between mutant mtDNA load and disease severity is poor in many mtDNA diseases. Second, the heteroplasmy level differs between tissues and in one tissue through time (Poulton and Marchington [@CR100]). In this context, the m.8993 mutation (NARP mutation) is an exception. There is a correlation between mutant mtDNA load and disease severity (Poulton and Marchington [@CR100]). Moreover, it has been shown that the placental/ amniotic mutant loads do reflect the NARP mutant mtDNA load in the whole fetus (Dahl et al. [@CR39]; Steffann et al. [@CR123]). Finally, it is suggested that the heteroplasmy level remains stable after 10 weeks of gestation (Steffann et al. [@CR123]). A mutation load \<30% gave rise to healthy children at 2-7 years of age, while the correlation between an intermediate mutant load (\>30% and \<80%) and disease severity still needs to be assessed (Steffann et al. [@CR123]). Hitherto termination of pregnancy has been preferred in case of intermediate mutant loads (Steffann et al. [@CR123]). Remarkably, the intermediate mutant loads question the observation that the m.8993T\>G mutation has a skewed segregation during oogenesis (Blok et al. [@CR16]). Post-zygotic drift might explain this discrepancy (Steffann et al. [@CR123]). Current options for women with *MT-ATP6* or *MT-ATP8* mutations can be oocyte donation or preimplantation genetic diagnosis (PGD), since the different heteroplasmy levels between tissues are not yet present in blastomeres (Jenuth et al. [@CR62]; Poulton and Marchington [@CR100]; Dean et al. [@CR44]). The interpretation of PGD results nevertheless demands a known correlation between mutation load and clinical phenotype. In addition, caution is warranted since some pathogenic mutations could exhibit different segregation behavior (Dean et al. [@CR44]). In case the genetic examination of an index case has revealed no mutations in both mtDNA and nDNA, prenatal diagnosis could still be possible. In Nijmegen, complex V activity can be measured spectrophotometrically in native chorionic villi, cultured chorionic cells or cultured amniotic cells if there is a clear isolated complex V deficiency in fibroblasts and muscle tissue (or other tissue) of the index patient (Niers et al. [@CR91]; Rodenburg [@CR110]).

Concluding remarks and future perspectives {#Sec25}
==========================================

Thanks to the extensive research over the last decades, nowadays much is known regarding the structure and function of the world's smallest rotary nanomotor. As mentioned briefly, most of the structure of the bovine mitochondrial enzyme has been resolved. The structure of the membrane extrinsic part of bovine ATP synthase is complete (Rees et al. [@CR109]). The structure of the c-ring has been resolved recently (Watt et al. [@CR146]). The structures of the membrane domain of subunit b, subunit a, and the accessory subunits e, f, g, and A6L remain to be determined (Rees et al. [@CR109]). The mechanism of the rotary F~1~F~o~ ATP synthase has been described by Boyer (Boyer [@CR18]). Still, understanding the enzyme fully at a molecular level will require further efforts, both experimental and theoretical (for a review, see (Junge et al. [@CR65])). Next to structure and function of the monocomplex, also the role of di- and oligomerization of complex V, shaping the inner mitochondrial membrane, has been addressed in many studies both in yeast and in mammalian mitochondria (Paumard et al. [@CR97]; Strauss et al. [@CR126]). The role of IF~1~ in this process has been shown to be important (Campanella et al. [@CR26], [@CR27]).

Despite this huge progress, lots of questions remain to be answered. As mentioned, the assembly of the different subunits into the holocomplex continues to be puzzling. Most of the research has been done in yeast. However, the yeast assembly process probably differs from the one in mammalian mitochondria, since there are substantial differences between higher and lower eukaryotes such as the number of F~o~ subunit c-genes, ATP synthase-specific assembly factors, and factors regulating transcription of ATP synthase genes (Houstek et al. [@CR57]). To gain further insight into the assembly of complex V, techniques like blue native and clear native PAGE, combined with incorporation and knock-down experiments of different subunits as described in (Wagner et al. [@CR141]) could refine our current knowledge. Further, only two assembly factors, ATP11 and ATP12, are hitherto known in mammalian ATP synthase. They both have a role in F~1~ assembly. TMEM70 maintains normal expression levels of complex V, and has been suggested to have a role in complex V biogenesis (Cizkova et al. [@CR33]). The exact mechanism however still remains to be elucidated. Moreover, the existence of specific factors involved in mammalian F~o~ formation is probable (Houstek et al. [@CR57]). A possible approach could be to study the evolution of complex V subunits and complex V chaperones by comparative genomics. For example, the yeast F~o~ assembly factor Atp23p has a human homolog for which, however, no involvement in ATP synthase assembly could be demonstrated (Kucharczyk et al. [@CR70], [@CR71], [@CR72]). Also a homology of complex V chaperones with other human proteins could be of interest in the search of specific assembly factors. Another intriguing fact is that to date, only one mutation has been found in a nuclear structural complex V gene (Mayr et al. [@CR83]). It could be possible that mutations in some of the structural subunits are incompatible with life. On the other hand, given the lower frequency of complex V deficiency compared to the other OXPHOS deficiencies, routine screening of all nuclear structural genes is rarely implemented in a diagnostic setting. Whole genome or whole exome screening could counter this problem and possibly solve some of the hitherto unknown genetic defects causing complex V deficiency. Finally, the biggest challenge will be to find a tailored curative therapy for this patient group. Large-scale and high-throughput compound screening is needed to find a possible pharmacological approach. For mtDNA defects, gene-shifting and germline techniques are promising, but much more and thorough experimental research is needed before this can be implemented in the patient setting.

In conclusion, mitochondrial ATP synthase has been and still is a popular research topic. Thanks to sustained effort, many aspects of this intriguing protein have been elucidated. This knowledge will guide further physio(patho)logical studies, paving the way for future therapeutic interventions.
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